Clinical Challenges: Using Pola-R-CHP for Diffuse Large B-Ce

Regimen is approved for frontline treatment, but when it represents the best choice is less clear

Related Keywords

Philadelphia , Pennsylvania , United States , Tampa , Florida , Delaware , Leah Lawrence , Jakub Svoboda , Michael Jain , Moffitt Cancer Center , National Comprehensive Cancer Network , Penn Medicine , B Cell Lymphoma , Diffuse Largeb Cell Lymphoma , Vincristine , Neuropathy , Rituximab ,